Clinical and Translational Oncology

, Volume 21, Issue 3, pp 373–379 | Cite as

Retroperitoneal fibrosis secondary to non-urology carcinomas: a clinical and outcome analysis of 97 cases

  • T. Chen
  • L. Tian
  • D. Fan
  • F. Wu
  • J. LuEmail author
  • S. Ding
Research Article



Accumulated evidences have reminded us that since the prognosis of retroperitoneal fibrosis (RPF) secondary to non-urology carcinoma is poor it is essential to distinguish this condition from others. The objective of this study is to investigate the clinical features and outcomes of this infrequent but life-threatening disease.


A total of 97 patients diagnosed with RPF secondary to non-urology carcinoma were enrolled in this retrospective study. The baseline information, history of carcinoma, clinical presentation, laboratory results, diagnosis, treatment and prognosis of the patients were collected and analyzed.


The mean age was 62.32 ± 11.22 years (range 31–85 years). It took 16.72 ± 7.11 days (range 3–34 days) for the patients with originally unexplained hydronephrosis to get a definite diagnosis of RPF secondary to non-urology carcinoma. Imaging-confirmed RPF [confirmed by computed tomography (CT) or magnetic resonance imaging (MRI)] was found in 91 patients. Fifty-seven patients were diagnosed with histological-confirmed malignant RPF. Sixty-six patients received surgical interventions. Cystoscopy and double J tube were performed in 68 cases (102 sides, 172 times) and was failed in 93 times (54.07%). Pyelostomy was performed in 72 patients (92 sides) without a single failure. Furthermore, eighty patients received chemotherapy and/or radiotherapy. The 6-month survival since RPF secondary to non-urology carcinoma was confirmed was 30%.


All patients with newly diagnosed unexplained hydronephrosis should undergo an age-appropriate carcinoma screening. The prognosis of RPF secondary to non-urology carcinoma was dismal. When dealing with hydronephrosis affecting renal function, pyelostomy instead of double J tube catheterization should be performed ahead of time.


Carcinoma Hydronephrosis Prognosis Retroperitoneal fibrosis 



We appreciate a grant from Shandong Province Key Research and Development Program (No.2016GGB14312) and a grant from Shandong Province Medicine Heath Science Technology Development Program (No. 2016WS0425) for supporting our study. Besides, we thank Zhao Liu from Department of Urology, Qilu Hospital of Shandong University for proof reading of our manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was conducted in compliance with ethical principles based on the 1964 Declaration of Helsinki and with the approval of the ethics committee of Shandong Provincial Hospital Shandong University.

Informed consent

Informed consent was obtained from all individual participants included in this study.


  1. 1.
    Higgins PM, Bennett-Jones DN, Naish PF, Aber GM. Non-operative management of retroperitoneal fibrosis. Br J Surg. 1988;75(6):573–7.CrossRefGoogle Scholar
  2. 2.
    Kottra JJ, Dunnick NR. Retroperitoneal fibrosis. Radiol Clin N Am. 1996;34(6):1259–75.Google Scholar
  3. 3.
    Lepor H, Walsh PC, Lepor H, Walsh PC. Idiopathic retroperitoneal fibrosis. J Urol. 1979;122(1):1–6.CrossRefGoogle Scholar
  4. 4.
    van Bommel EF. Retroperitoneal fibrosis. Neth J Med. 2002;60(6):231.Google Scholar
  5. 5.
    Yokoyama R, Tazaki R, Morita H, Nishitani H, Ariumi S, Osuga S, et al. Retroperitoneal fibrosis in a patient with gastric cancer manifested by lower extremity edema and hydrocele. Intern Med (Tokyo, Jpn). 2012;51(16):2157–60.CrossRefGoogle Scholar
  6. 6.
    Kuhn W, Loos W, Graeff H. Hydronephrosis as the first manifestation of primary metastatic breast cancer. Geburtshilfe Frauenheilkd. 1994;54(5):308–10. Scholar
  7. 7.
    Kane AJ, Wang ZJ, Qayyum A, Yeh BM, Webb EM, Coakley FV. Frequency and etiology of unexplained bilateral hydronephrosis in patients with breast cancer: results of a longitudinal CT study. Clin Imaging. 2012;36(4):263–6. Scholar
  8. 8.
    Gilkeson GS, Allen NB. Retroperitoneal fibrosis. A true connective tissue disease. Rheum Dis Clin N Am. 1996;22(1):23.CrossRefGoogle Scholar
  9. 9.
    Stone JR. Aortitis, periaortitis, and retroperitoneal fibrosis, as manifestations of IgG4-related systemic disease. Curr Opin Rheumatol. 2011;23(1):88–94. Scholar
  10. 10.
    Vaglio A, Palmisano A, Alberici F, Maggiore U, Ferretti S, Cobelli R, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet (Lond, Engl). 2011;378(9788):338–46. Scholar
  11. 11.
    Ormond JK. Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. J Urol. 1948;59(6):1072–9.CrossRefGoogle Scholar
  12. 12.
    Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet (Lond, Engl). 2006;367(9506):241–51. Scholar
  13. 13.
    Thomas MH, Chisholm GD. Retroperitoneal fibrosis associated with malignant disease. Br J Cancer. 1973;28(5):453–8.CrossRefGoogle Scholar
  14. 14.
    Dohmen K, Mizukami Y, Tanaka K, Nakamura H, Arase K, Yokogawa Y, et al. Retroperitoneal fibrosis associated with scirrhous gastric cancer. Gastroenterol Jpn. 1993;28(5):699–705.CrossRefGoogle Scholar
  15. 15.
    Terry MB, Gaudet MM, Gammon MD. The epidemiology of gastric cancer. Semin Radiat Oncol. 2002;12(2):111–27. Scholar
  16. 16.
    Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy—Japan Clinical Oncology Group study 9501. J Clin Oncol. 2004;22(14):2767–73. Scholar
  17. 17.
    Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M. Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as “soil” for peritoneal dissemination. Cancer. 1996;77(8 Suppl):1668–75.;2-w.CrossRefGoogle Scholar
  18. 18.
    Yamauchi S, Nakagawa T, Kasahara M, Sugimoto H, Ishiba T, Tamura N, et al. A case of metastatic breast cancer with bilateral hydronephrosis effectively treated with capecitabine. Gan to kagaku ryoho Cancer & Chemother. 2012;39(12):2077–9.Google Scholar
  19. 19.
    Urban ML, Palmisano A, Nicastro M, Corradi D, Buzio C, Vaglio A. Idiopathic and secondary forms of retroperitoneal fibrosis: a diagnostic approach. La Revue de medecine interne. 2015;36(1):15–21. Scholar
  20. 20.
    Chisholm GD, Shackman R. Malignant obstructive uraemia. Br J Urol. 1968;40(6):720–6.CrossRefGoogle Scholar
  21. 21.
    Rose PG, Ali S, Whitney CW, Lanciano R, Stehman FB. Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;117(2):270–5. Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2018

Authors and Affiliations

  1. 1.Department of Pediatric SurgeryShanghai Children’s Hospital, Shanghai Jiao Tong UniversityShanghaiPeople’s Republic of China
  2. 2.Guilin Medical UniversityGuilinPeople’s Republic of China
  3. 3.Department of UrologyShandong Provincial Qianfoshan HospitalJinanPeople’s Republic of China
  4. 4.Department of UrologyShandong Provincial Hospital Affiliated to Shandong UniversityJinanPeople’s Republic of China

Personalised recommendations